BioCentury
ARTICLE | Clinical News

F17464: Phase IIa started

February 16, 2015 8:00 AM UTC

Pierre Fabre began a double-blind, placebo-controlled, European Phase IIa trial to evaluate oral F17464 daily for 6 weeks in 142 patients with a recent acute schizophrenic episode. ...